- Company committed to building presence in U.S. and Europe to advance mission of improving mental health care
- New appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industry
- New leaders bring broad experience, deep insight to their new roles
Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, recently made key senior-management changes designed to provide the company with added insight and expertise in the expansion of its development and clinical operations in the United States and Europe (https://ibn.fm/FsF0L). The appointments, which are effective immediately, call for Alexander Belser, PhD, to serve as chief clinical officer and Aaron Bartlone to serve as chief operating officer.
“We are committed to building our presence both in the United States and in Europe to advance our mission of improving mental health care through therapeutic development programs and innovative drug-delivery systems,” said Cybin CEO Doug Drysdale. “These appointments will serve to strengthen our development and clinical operations globally and solidify Cybin’s position within the industry. Alex and Aaron bring deep clinical, commercial, and regulatory expertise that will serve to broaden our management and scientific leadership teams. We look forward to their contributions as we pursue increased visibility across these additional markets.”
An accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, Bartlone brings impressive quality assurance, regulatory affairs, product development, compliance, and commercial operation experience to his new role. Prior to joining Cybin, Bartlone served as both president and managing director for AB Dynamix LLC. In those roles, he oversaw the development of customized and innovative quality-management systems, regulatory strategies, and supply chains for developing pharmaceutical, biotechnology, and medical-device companies.
Bartlone has also worked at UCB Inc., a global pharmaceutical company, and Eli Lilly. He has developed global teams of more than 1,000 colleagues in 50 different countries and has successfully driven more than 25 small and large molecular therapies and drug-device combination products to the global marketplace.
A well-known leader in the field of psychedelic research, Belser has invaluable insight and expertise as an investigator on NYU and Yale University clinical trials of psilocybin and MDMA designed to treat depression, anxiety, substance use, obsessive-compulsive disorder, post-traumatic stress disorder, and end-of-life distress. A former chief clinical officer at Adelia Therapeutics, Belser directed the clinical program investigating tryptamines and phenethylamines for a variety of treatment indications.
In addition, Belser is the founding president of Nautilus Sanctuary, the first nonprofit center for psychedelic medicine in the Eastern United States, and is a recognized expert on psychedelic medicine, having authored a dozen peer-reviewed publications and delivered more than 50 lectures, presentations, and grand rounds on psychedelic topics.
In addition, Cybin also noted that cofounder and former COO Paul Glavine will assume the role of chief growth officer and John Kanakis, cofounder and former SVP of business development, will assume the role of chief business officer.
“Paul and John’s extensive entrepreneurial experience was instrumental in shaping the initial formation of Cybin and the company’s subsequent emergence as a leader within the psychedelics space,” Drysdale stated. “Their deep commitment to Cybin’s mission will continue as they assume these new roles and will allow them to further accelerate business-development and investor-awareness initiatives. We believe these appointments are an important step in taking Cybin to the next level.”
Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.